Michael Rice Sells 7,088 Shares of BioLife Solutions Inc (BLFS) Stock

BioLife Solutions Inc (NASDAQ:BLFS) CEO Michael Rice sold 7,088 shares of the company’s stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $16.94, for a total transaction of $120,070.72. Following the completion of the sale, the chief executive officer now directly owns 182,102 shares of the company’s stock, valued at $3,084,807.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Michael Rice also recently made the following trade(s):

  • On Wednesday, April 10th, Michael Rice sold 7,088 shares of BioLife Solutions stock. The stock was sold at an average price of $17.91, for a total transaction of $126,946.08.
  • On Wednesday, March 13th, Michael Rice sold 7,088 shares of BioLife Solutions stock. The stock was sold at an average price of $17.19, for a total transaction of $121,842.72.

NASDAQ:BLFS traded up $0.48 during mid-day trading on Friday, reaching $18.22. The company’s stock had a trading volume of 129,500 shares, compared to its average volume of 159,005. BioLife Solutions Inc has a 1 year low of $8.50 and a 1 year high of $26.35. The firm has a market cap of $336.52 million, a PE ratio of 130.14 and a beta of 1.53. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.50 and a quick ratio of 12.99.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings data on Thursday, May 9th. The medical equipment provider reported $0.03 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.03. The firm had revenue of $5.77 million during the quarter, compared to analyst estimates of $5.67 million. BioLife Solutions had a net margin of 17.01% and a return on equity of 10.32%. Sell-side analysts anticipate that BioLife Solutions Inc will post 0.13 EPS for the current fiscal year.

BLFS has been the subject of a number of research reports. Northland Securities reaffirmed a “buy” rating and issued a $18.00 price objective on shares of BioLife Solutions in a research note on Monday. ValuEngine lowered shares of BioLife Solutions from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, March 27th. BidaskClub raised shares of BioLife Solutions from a “hold” rating to a “buy” rating in a research note on Friday, March 1st. Finally, Zacks Investment Research raised shares of BioLife Solutions from a “sell” rating to a “buy” rating and set a $20.00 price objective for the company in a research note on Wednesday. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $18.20.

Several institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc raised its position in shares of BioLife Solutions by 43.1% in the 3rd quarter. Vanguard Group Inc now owns 447,984 shares of the medical equipment provider’s stock valued at $7,839,000 after purchasing an additional 134,869 shares during the last quarter. Vanguard Group Inc. raised its position in shares of BioLife Solutions by 43.1% in the 3rd quarter. Vanguard Group Inc. now owns 447,984 shares of the medical equipment provider’s stock valued at $7,839,000 after purchasing an additional 134,869 shares during the last quarter. Essex Investment Management Co. LLC raised its position in shares of BioLife Solutions by 11.9% in the 4th quarter. Essex Investment Management Co. LLC now owns 308,185 shares of the medical equipment provider’s stock valued at $3,707,000 after purchasing an additional 32,788 shares during the last quarter. BlackRock Inc. raised its position in shares of BioLife Solutions by 54.4% in the 1st quarter. BlackRock Inc. now owns 236,029 shares of the medical equipment provider’s stock valued at $4,223,000 after purchasing an additional 83,151 shares during the last quarter. Finally, Cadence Capital Management LLC raised its position in shares of BioLife Solutions by 1.8% in the 1st quarter. Cadence Capital Management LLC now owns 195,269 shares of the medical equipment provider’s stock valued at $3,493,000 after purchasing an additional 3,439 shares during the last quarter. 41.21% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Michael Rice Sells 7,088 Shares of BioLife Solutions Inc (BLFS) Stock” was first published by Modern Readers and is the property of of Modern Readers. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://www.modernreaders.com/news/2019/05/18/michael-rice-sells-7088-shares-of-biolife-solutions-inc-blfs-stock-2.html.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Featured Article: What is a stock buyback?

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.